Biodegradable nanogels for oral delivery of interferon for norovirus infection

Antiviral Research

Volumn 89, Issue 2, 2011, Pages 165-173

  Kim, Yunjeong ^a   Thapa, Mahendra ^a   Hua, Duy H ^a   Chang, Kyeong Ok ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

Antiviral; Interferon; Murine norovirus; Nanogel; Norwalk virus; Replicon harboring cells

Indexed keywords

INTERFERON; MACROGOL; NANOMATERIAL; POLYETHYLENEIMINE;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CELL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG STORAGE; FEMALE; FREEZE DRYING; MOUSE; NONHUMAN; NOROVIRUS INFECTION; PRIORITY JOURNAL; RAT; REPLICON; RNA VIRUS INFECTION; SYNTHESIS;

ACETYLATION; ANIMALS; CELL LINE; DRUG CARRIERS; DRUG STABILITY; INTERFERONS; MACROPHAGES; MICE; MICROSCOPY, ATOMIC FORCE; MOLECULAR STRUCTURE; NOROVIRUS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE;

HEPATITIS C VIRUS; MURINE NOROVIRUS; NOROVIRUS; NORWALK VIRUS;

EID: 78751610778     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.11.016     Document Type: Article

References (52)

1. Aghemo A., Rumi M.G., Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat. Rev. Gastroenterol. Hepatol. 2010.
2. Arnaoudova V. Treatment and prevention of acute respiratory virus infections in children with leukocytic interferon. Virologie 1976, 27(2):83-88.
3. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., Ehrlich G.K., Pan W., Xu Z.X., Modi M.W., Farid A., Berthold W., Graves M. Rational design of a potent, long-lasting form of interferon: a 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugate Chem. 2001, 12(2):195-202.
4. Beilharz M.W., Cummins J.M., Bennett A.L. Protection from lethal influenza virus challenge by oral type 1 interferon. Biochem. Biophys. Res. Commun. 2007, 355(3):740-744.
5. Beilharz M.W.C., Reilly M.J., Bennett A.L., Cummins J.M. Oromucosal administration of interferon to humans. Pharmaceuticals 2010, 3:323-344.
6. CDC Surveillance for Foodborne Disease Outbreaks-United States, 2007, vol. 59 2010, Morbidity and mortality weekly report, pp. 973-979.
7. Chang K.O., George D.W. Bile acids promote the expression of hepatitis C virus in replicon-harboring cells. J. Virol. 2007, 81(18):9633-9640.
8. Chang K.O., George D.W. Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells. J. Virol. 2007, 81(22):12111-12118.
9. Chang K.O., Sosnovtsev S.V., Belliot G., King A.D., Green K.Y. Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology 2006, 353(2):463-473.
10. Chang K.O. Role of cholesterol pathways in norovirus replication. J. Virol. 2009, 83(17):8587-8595.
11. Changotra H., Jia Y., Moore T.N., Liu G., Kahan S.M., Sosnovtsev S.V., Karst S.M. Type I and type II interferons inhibit the translation of murine norovirus proteins. J. Virol. 2009, 83(11):5683-5692.
12. Dec M., Puchalski A. Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases. Polym. J. Vet. Sci. 2008, 11(2):175-186.
13. Duizer E., Schwab K.J., Neill F.H., Atmar R.L., Koopmans M.P., Estes M.K. Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 2004, 85(Pt 1):79-87.
14. Fankhauser R.L., Noel J.S., Monroe S.S., Ando T., Glass R.I. Molecular epidemiology of " Norwalk-like viruses" in outbreaks of gastroenteritis in the United States. J. Infect. Dis. 1998, 178(6):1571-1578.
15. Foster G.R. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs 2010, 70(2):147-165.
16. Ganta C., Shi A., Battina S.K., Pyle M., Rana S., Hua D.H., Tamura M., Troyer D. Combination of nanogel polyethylene glycol-polyethylenimine and 6(hydroxymethyl)-1,4-anthracenedione as an anticancer nanomedicine. J. Nanosci. Nanotechnol. 2008, 8(5):2334-2340.
17. Gonzalez-Cabanas R., Miro A., Ferrero J., Gonzalez R., Marin N., Maccias C., Lopez-Saura P. Biological effects of oral leukocyte interferon-β in healthy volunteers. Eur. Cytokine Netw. 1996, 7:650.
18. Grimm D., Staeheli P., Hufbauer M., Koerner I., Martinez-Sobrido L., Solorzano A., Garcia-Sastre A., Haller O., Kochs G. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(16):6806-6811.
19. Hayden F.G., Mills S.E., Johns M.E. Human tolerance and histopathologic effects of long-term administration of intranasal interferon-alpha 2. J. Infect. Dis. 1983, 148(5):914-921.
20. Herzog C., Just M., Berger R., Havas L., Fernex M. Intranasal interferon for contact prophylaxis against common cold in families. Lancet 1983, 2(8356):962.
21. Husa P., Husova L. Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons. Bratisl. Lek. Listy 2001, 102(5):248-252.
22. Imanishi J., Karaki T., Sasaki O., Matsuo A., Oishi K., Pak C.B., Kishida T., Toda S., Nagata H. The preventive effect of human interferon-alpha preparation on upper respiratory disease. J. Interferon Res. 1980, 1(1):169-178.
23. Isomura S., Ichikawa T., Miyazu M., Naruse H., Shibata M., Imanishi J., Matsuo A., Kishida T., Karaki T. The preventive effect of human interferon-alpha on influenza infection; modification of clinical manifestations of influenza in children in a closed community. Biken J. 1982, 25(3):131-137.
24. Jen J.F., Glue P., Ezzet F., Chung C., Gupta S.K., Jacobs S., Hajian G. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C. Clin. Pharmacol. Ther. 2001, 69(6):407-421.
25. Karst S.M., Wobus C.E., Lay M., Davidson J., Virgin H.W.t. STAT1-dependent innate immunity to a Norwalk-like virus. Science 2003, 299(5612):1575-1578.
26. Kozlowski A., Charles S.A., Harris J.M. Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs 2001, 15(7):419-429.
27. Kugel D., Kochs G., Obojes K., Roth J., Kobinger G.P., Kobasa D., Haller O., Staeheli P., von Messling V. Intranasal administration of alpha interferon reduces seasonal influenza A virus morbidity in ferrets. J. Virol. 2009, 83(8):3843-3851.
28. Liu C.J., Kao J.H. Pegylated interferons for the treatment of chronic hepatitis B. Recent Pat. Antiinfect. Drug Discov. 2006, 1(1):85-94.
29. Lowe P.J., Temple C.S. Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in rats. J. Pharm. Pharmacol. 1994, 46(7):547-552.
30. Luxon B.A., Grace M., Brassard D., Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin. Ther. 2002, 24(9):1363-1383.
31. Mead P.S., Slutsker L., Dietz V., McCaig L.F., Bresee J.S., Shapiro C., Griffin P.M., Tauxe R.V. Food-related illness and death in the United States. Emerg. Infect. Dis. 1999, 5(5):607-625.
32. Merigan T.C., Reed S.E., Hall T.S., Tyrrell D.A. Inhibition of respiratory virus infection by locally applied interferon. Lancet 1973, 1(7803):563-567.
33. Monkarsh S.P., Ma Y., Aglione A., Bailon P., Ciolek D., DeBarbieri B., Graves M.C., Hollfelder K., Michel H., Palleroni A., Porter J.E., Russoman E., Roy S., Pan Y.C. Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Anal. Biochem. 1997, 247(2):434-440.
34. Mumphrey S.M., Changotra H., Moore T.N., Heimann-Nichols E.R., Wobus C.E., Reilly M.J., Moghadamfalahi M., Shukla D., Karst S.M. Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. J. Virol. 2007, 81(7):3251-3263.
35. Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Pract. Res. Clin. Gastroenterol. 2010, 24(2):183-192.
36. Nilsson M., Hedlund K.O., Thorhagen M., Larson G., Johansen K., Ekspong A., Svensson L. Evolution of human calicivirus RNA in vivo: accumulation of mutations in the protruding P2 domain of the capsid leads to structural changes and possibly a new phenotype. J. Virol. 2003, 77(24):13117-13124.
37. Phillpotts R.J., Scott G.M., Higgins P.G., Wallace J., Tyrrell D.A., Gauci C.L. An effective dosage regimen for prophylaxis against rhinovirus infection by intranasal administration of HuIFN-alpha 2. Antiviral Res. 1983, 3(2):121-136.
38. Phillpotts R.J., Higgins P.G., Willman J.S., Tyrrell D.A., Freestone D.S., Shepherd W.M. Intranasal lymphoblastoid interferon (" Wellferon") prophylaxis against rhinovirus and influenza virus in volunteers. J. Interferon Res. 1984, 4(4):535-541.
39. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
40. Saito H., Takenaka H., Yoshida S., Tsubokawa T., Ogata A., Imanishi F., Imanishi J. Prevention from naturally acquired viral respiratory infection by interferon nasal spray. Rhinology 1985, 23(4):291-295.
41. Sharieff K.A., Duncan D., Younossi Z. Advances in treatment of chronic hepatitis C: 'pegylated' interferons. Cleve Clin. J. Med. 2002, 69(2):155-159.
42. Shiffman M.L. Pegylated interferons: what role will they play in the treatment of chronic hepatitis C?. Curr. Gastroenterol. Rep. 2001, 3(1):30-37.
43. Sosnovtsev S.V., Belliot G., Chang K.O., Prikhodko V.G., Thackray L.B., Wobus C.E., Karst S.M., Virgin H.W., Green K.Y. Cleavage map and proteolytic processing of the murine norovirus nonstructural polyprotein in infected cells. J. Virol. 2006, 80(16):7816-7831.
44. Spann K.M., Tran K.C., Chi B., Rabin R.L., Collins P.L. Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected]. J. Virol. 2004, 78(8):4363-4369.
45. Treanor J.J., Betts R.F., Erb S.M., Roth F.K., Dolin R. Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. J. Infect. Dis. 1987, 156(2):379-383.
46. Tumpey T.M., Szretter K.J., Van Hoeven N., Katz J.M., Kochs G., Haller O., Garcia-Sastre A., Staeheli P. The Mx1 gene protects mice against the pandemic 1918 and highly lethal human H5N1 influenza viruses. J. Virol. 2007, 81(19):10818-10821.
47. Uno K., Suginoshita Y., Kakimi K., Moriyasu Y., Nakano K., Nakamura N., Fujita T., Horino Y., Sato T., Kishida T. Clinical utility of 2′,5′-oligoadenylate synthetase activity measurement: using whole blood as a highly sensitive method to detect the effects of IFN. J. Virol. Methods 2006, 136(1-2):185-192.
48. Van Hoeven N., Belser J.A., Szretter K.J., Zeng H., Staeheli P., Swayne D.E., Katz J.M., Tumpey T.M. Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding. J. Virol. 2009, 83(7):2851-2861.
49. Vinogradov S., Batrakova E., Kabanov A. Poly(ethylene glycol)-polyethyleneimine NanoGel™ particles: novel drug delivery systems for antisense oligonucleotides. Colloids Surf. B: Biointerf. 1999, 16(1-4):291-304.
50. Vinogradov S.V., Kohli E., Zeman A.D. Comparison of nanogel drug carriers and their formulations with nucleoside 5′-triphosphates. Pharm. Res. 2006, 23(5):920-930.
51. Witt P.L., Goldstein D., Storer B.E., Grossberg S.E., Flashner M., Colby C.B., Borden E.C. Absence of biological effects of orally administered interferon-beta ser. J. Interferon Res. 1992, 12(6):411-413.
52. Wobus C.E., Karst S.M., Thackray L.B., Chang K.O., Sosnovtsev S.V., Belliot G., Krug A., Mackenzie J.M., Green K.Y., Virgin H.W.t. Replication of norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLoS Biol. 2004, 2(12):e432.